Currently, we are investigating therapies for Tourette syndrome in pediatric patients and childhood-onset fluency disorder—also known as stuttering—in adults. To date, there is only one U.S. Food and Drug Administration (FDA)-approved treatment for Tourette’s and no FDA-approved treatment for childhood-onset fluency disorder.
Latest News
Emalex Biosciences to Present Positive Results for Pediatric Tourette Syndrome Study at AAN Annual Meeting
Emalex Biosciences Expands CNS Platform to Advance Treatment for Restless Legs Syndrome with Augmentation
Paragon’s Portfolio Company Emalex Biosciences Announces Positive Topline Results from Phase 2b Clinical Study Evaluating Ecopipam for Pediatric Tourette Syndrome
Currently, we are investigating therapies for Tourette syndrome in pediatric patients and childhood-onset fluency disorder—also known as stuttering—in adults. To date, there is only one U.S. Food and Drug Administration (FDA)-approved treatment for Tourette’s and no FDA-approved treatment for childhood-onset fluency disorder.
Latest News
Emalex Biosciences to Present Positive Results for Pediatric Tourette Syndrome Study at AAN Annual Meeting
By emalexadmin |
Currently, we are investigating therapies for Tourette syndrome in pediatric patients and childhood-onset fluency disorder—also known as stuttering—in adults. To date, there is only one U.S. Food and Drug Administration (FDA)-approved treatment for Tourette’s and no FDA-approved treatment for childhood-onset fluency disorder.